Safety and tolerability of prescription omega-3 fatty acids: A systematic review and meta-analysis of randomized controlled trials

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 129, Issue , 2018, Pages 1-12

  Chang, Cheng Ho ^a,b   Tseng, Ping Tao ^c   Chen, Nai Yu ^a,d   Lin, Pei Chin ^a,e   Lin, Pao Yen ^f   Chang, Jane Pei Chen ^g,h   Kuo, Feng Yu ^a   Lin, Jenshinn ^b   Wu, Ming Chang ^b   Su, Kuan Pin ^h  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^c Winshine clinics in specialty of psychiatry   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adverse effect; Adverse event; Omega 3 fatty acid; Prescription; Safety; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; DOCOSAHEXAENOIC ACID; GLUCOSE; ICOSAPENTAENOIC ACID; NITROGEN; OMEGA 3 FATTY ACID; UREA; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; ECZEMA; ERUCTATION; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; RASH; SKIN DISEASE; SYSTEMATIC REVIEW; BLOOD; DIETARY SUPPLEMENT; GLUCOSE BLOOD LEVEL; METABOLISM; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

BLOOD GLUCOSE; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DYSGEUSIA; ECZEMA; EICOSAPENTAENOIC ACID; EXANTHEMA; HUMANS; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85041469847     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2018.01.001     Document Type: Article

References (68)

1. Connor, W.E., Importance of n−3 fatty acids in health and disease. Am. J. Clin. Nutr. 71 (2000), 171S–175S.
2. Simopoulos, A.P., Omega-3 fatty acids in inflammation and autoimmune diseases. J. Am. Coll. Nutr. 21 (2002), 495–505.
3. Kris-Etherton, P.M., Harris, W.S., Appel, L.J., Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 23 (2003), e20–e30.
4. Goldberg, R.J., Katz, J., A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain 129 (2007), 210–223.
5. Saravanan, P., Davidson, N.C., Schmidt, E.B., Calder, P.C., Cardiovascular effects of marine omega-3 fatty acids. Lancet 376 (2010), 540–550.
6. Parker, H.M., Johnson, N.A., Burdon, C.A., Cohn, J.S., O'Connor, H.T., George, J., Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J. Hepatol. 56 (2012), 944–951.
7. Rizos, E.C., Ntzani, E.E., Bika, E., Kostapanos, M.S., Elisaf, M.S., Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308 (2012), 1024–1033.
8. Rice, H.B., Bernasconi, A., Maki, K.C., Harris, W.S., von Schacky, C., Calder, P.C., Conducting omega-3 clinical trials with cardiovascular outcomes: proceedings of a workshop held at ISSFAL 2014. Prostaglandins Leukot. Essent. Fat. Acids 107 (2016), 30–42.
9. Harris, W.S., Dayspring, T.D., Moran, T.J., Omega-3 fatty acids and cardiovascular disease: new developments and applications. Postgrad. Med. 125 (2013), 100–113.
10. Lin, P.Y., Chang, C.H., Chong, M.F., Chen, H., Su, K.P., Polyunsaturated fatty acids in perinatal depression: a systematic review and meta-analysis. Biol. Psychiatry 82 (2017), 560–569.
11. Chang, J.C., Su, K.P., Mondelli, V., Pariante, C.M., Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder (ADHD): a systematic review and meta-analysis of clinical trials and biological studies. Neuropsychopharmacology, 2017, 10.1038/npp.2017.160.
12. Su, K.P., Wang, S.M., Pae, C.U., Omega-3 polyunsaturated fatty acids for major depressive disorder. Expert Opin. Investig. Drugs 22 (2013), 1519–1534.
13. Su, K.P., Lai, H.C., Yang, H.T., et al. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol. Psychiatry 76 (2014), 559–566.
14. Lin, P.Y., Chiu, C.C., Huang, S.Y., Su, K.P., A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J. Clin. Psychiatry 73 (2012), 1245–1254.
15. Su, K.P., Shen, W.W., Huang, S.Y., Effects of polyunsaturated fatty acids on psychiatric disorders. Am. J. Clin. Nutr., 72, 2000, 1241.
16. Lin, P.Y., Mischoulon, D., Freeman, M.P., et al. Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression. Mol. Psychiatry 17 (2012), 1161–1163 (author reply1163-1167).
17. Bradberry, J.C., Hilleman, D.E., Overview of omega-3 fatty acid therapies. P T 38 (2013), 681–691.
18. Brunton, S., Collins, N., Differentiating prescription omega-3-acid ethyl esters (P-OM3) from dietary-supplement omega-3 fatty acids. Curr. Med. Res. Opin. 23 (2007), 1139–1145.
19. Hoy, S.M., Keating, G.M., Omega-3 ethylester concentrate: a review of its use in secondary prevention post-myocardial infarction and the treatment of hypertriglyceridaemia. Drugs 69 (2009), 1077–1105.
20. Hilleman, D., Smer, A., Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care 25 (2016), 46–52.
21. Ito, M.K., A comparative overview of prescription omega-3 fatty acid products. P T 40 (2015), 826–857.
22. Farnier, M., Safety review of combination drugs for hyperlipidemia. Expert Opin. Drug Saf. 10 (2011), 363–371.
23. Micromedex® 2.0, (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. 〈http://www.micromedexsolutions.com/micromedex2/librarian〉 (accessed 6 October 2017).
24. Villani, A.M., Crotty, M., Cleland, L.G., et al. Fish oil administration in older adults: is there potential for adverse events? A systematic review of the literature. BMC Geriatr., 13, 2013, 41.
25. Kepler, C.K., Huang, R.C., Meredith, D., Kim, J.H., Sharma, A.K., Omega-3 and fish oil supplements do not cause increased bleeding during spinal decompression surgery. J. Spinal Disord. Tech. 25 (2012), 129–132.
26. Mariani, J., Doval, H.C., Nul, D., et al. N-3 polyunsaturated fatty acids to prevent atrial fibrillation: updated systematic review and meta-analysis of randomized controlled trials. J. Am. Heart Assoc., 2, 2013, e005033.
27. Brinton, E.A., Mason, R.P., Prescription omega-3 fatty acid products containing highly purified eicosapentaenoic acid (EPA). Lipids Health Dis., 16, 2017, 23.
28. Liberati, A., Altman, D.G., Tetzlaff, J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med, 6, 2009, e1000100.
29. Drugs.com., International Drug Names. 〈https://www.drugs.com/international/〉 (Accessed 17 September 2017).
30. Jadad, A.R., Moore, R.A., Carroll, D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin. Trials 17 (1996), 1–12.
31. Frankos, V.H., Street, D.A., O'Neill, R.K., FDA regulation of dietary supplements and requirements regarding adverse event reporting. Clin. Pharmacol. Ther. 87 (2010), 239–244.
32. Borenstein, M., Hedges, L.V., Higgins, J.P., Rothstein, H.R., A basic introduction to fixed-effect and random-effects models for meta-analysis. Res. Synth. Methods 1 (2010), 97–111.
33. Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat. Med. 21 (2002), 1539–1558.
34. Borenstein, M., Higgins, J.P., Hedges, L.V., Rothstein, H.R., Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Res. Synth. Methods 8 (2017), 5–18.
35. Higgins, J.P., Green, S., 10.4.3.1 Recommendations on testing for funnel plot asymmetry. Higgins, J.P., Green, S., (eds.) Cochrane Handbook for Systematic Reviews of Interventions, 2008, The Cochrane Collaboration and John Wiley & Sons Ltd.
36. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
37. Duval, S., Tweedie, R., Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56 (2000), 455–463.
38. Tobias, A., Assessing the influence of a single study in meta-analysis. STATA Tech. Bull. 47 (1999), 15–17.
39. Davey, J., Turner, R.M., Clarke, M.J., Higgins, J.P., Characteristics of meta-analyses and their component studies in the cochrane database of systematic reviews: a cross-sectional, descriptive analysis. BMC Med Res Methodol., 11, 2011, 160.
40. Ando, M., Sanaka, T., Nihei, H., Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J. Am. Soc. Nephrol. 10 (1999), 2177–2184.
41. Mischoulon, D., Papakostas, G.I., Dording, C.M., et al. A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J. Clin. Psychiatry 70 (2009), 1636–1644.
42. Harris, W.S., Ginsberg, H.N., Arunakul, N., et al. Safety and efficacy of Omacor in severe hypertriglyceridemia. J. Cardiovasc Risk 4 (1997), 385–391.
43. Borthwick, L., Group, U.K.S., The effects of an omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia. Clin. Drug Investig. 15 (1998), 397–404.
44. Johansen, O., Brekke, M., Seljeflot, I., Abdelnoor, M., Arnesen, H., n-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. J. Am. Coll. Cardiol. 33 (1999), 1619–1626.
45. van Dam, M., Stalenhoef, A.F.H., Wittekoek, J., Trip, M.D., Prins, M.H., Kastelein, J.J.P., Efficacy of concentrated n-3 fatty acids in hypertriglyceridaemia. Clin. Drug Investig. 21 (2001), 175–181.
46. Puri, B.K., Leavitt, B.R., Hayden, M.R., et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65 (2005), 286–292.
47. Davidson, M.H., Stein, E.A., Bays, H.E., et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin. Ther. 29 (2007), 1354–1367.
48. Yokoyama, M., Origasa, H., Matsuzaki, M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
49. Holman, R.R., Paul, S., Farmer, A., et al. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia 52 (2009), 50–59.
50. Maki, K.C., McKenney, J.M., Reeves, M.S., Lubin, B.C., Dicklin, M.R., Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am. J. Cardiol. 102 (2008), 429–433.
51. Maki, K.C., Lubin, B.C., Reeves, M.S., Dicklin, M.R., Harris, W.S., Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J. Clin. Lipidol. 3 (2009), 33–38.
52. Kowey, P.R., Reiffel, J.A., Ellenbogen, K.A., Naccarelli, G.V., Pratt, C.M., Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA 304 (2010), 2363–2372.
53. Maki, K.C., Lawless, A.L., Kelley, K.M., Dicklin, M.R., Schild, A.L., Rains, T.M., Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic beta-cell response in subjects with primary hypertriglyceridemia. Prostaglandins Leukot. Essent. Fat. Acids 85 (2011), 143–148.
54. Ballantyne, C.M., Bays, H.E., Kastelein, J.J., et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am. J. Cardiol. 110 (2012), 984–992.
55. Jacobson, T.A., A new pure omega-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Rev. Cardiovasc Ther. 10 (2012), 687–695.
56. Tatsuno, I., Saito, Y., Kudou, K., Ootake, J., Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study. J. Clin. Lipidol. 7 (2013), 199–207.
57. Tatsuno, I., Saito, Y., Kudou, K., Ootake, J., Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized long-term (ORL) study. J. Clin. Lipidol. 7 (2013), 615–625.
58. de Ferranti, S.D., Milliren, C.E., Denhoff, E.R., et al. Using high dose omega-3 fatty acid supplements to lower triglyceride levels in 10–19 year-olds. Clin. Pediatr. 53 (2014), 428–438.
59. Kastelein, J.J., Maki, K.C., Susekov, A., et al. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr lowering very high triglyceridEs (EVOLVE) trial. J. Clin. Lipidol. 8 (2014), 94–106.
60. Heydari, B., Abdullah, S., Pottala, J.V., et al. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: the omega-remodel randomized clinical trial. Circulation 134 (2016), 378–391.
61. Sandhu, N., Schetter, S.E., Liao, J., et al. Influence of obesity on breast density reduction by omega-3 fatty acids: evidence from a randomized clinical trial. Cancer Prev. Res., 9, 2016, 275.
62. Su, T.C., Hwang, J.J., Huang, K.C., et al. A randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ethyl-ester omega-3 fatty acid in taiwanese hypertriglyceridemic patients. J. Atheroscler. Thromb. 24 (2017), 275–289.
63. T.I.S.C. (SC), MedDRA. 〈https://www.meddra.org/〉 (Accessed 6 October 2017).
64. Brown, E.G., Wood, L., Wood, S., The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20 (1999), 109–117.
65. Li, Y.H., Ueng, K.C., Jeng, J.S., et al. 2017 Taiwan lipid guidelines for high risk patients. J. Formos. Med. Assoc. 116 (2017), 217–248.
66. Wei, M.Y., Jacobson, T.A., Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr. Atheroscler. Rep. 13 (2011), 474–483.
67. Jacobson, T.A., Glickstein, S.B., Rowe, J.D., Soni, P.N., Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. J. Clin. Lipidol. 6 (2012), 5–18.
68. Golder, S., Loke, Y.K., Bland, M., Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med., 8, 2011, e1001026.